Predicting pancreatogenic diabetes after partial pancreas removal
Official title: Prediction of Pancreatogenic Diabetes After Partial Resection of the Pancreas
Run by University Medical Centre Ljubljana · NCT07665710 · Data updated 2026-11-12
Aims to see if clinical, lab, imaging, and tissue findings before and after partial pancreas surgery can predict who will develop pancreatogenic diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | University Medical Centre Ljubljana Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Ljubljana) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | April 1, 2029 |
| Study ends | April 1, 2029 |
| Registry record updated | July 16, 2026 |
| Trial ID | NCT07665710 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 or older undergoing planned partial pancreatectomy with no prior diabetes or impaired glucose tolerance.
✕Probably not a fit
Patients who do not develop pancreatogenic diabetes or who are not predicted to be at risk may see no specific benefit from the model.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will collect demographic, clinical, imaging, and laboratory data from adults undergoing planned partial pancreatic resection. Researchers will measure HbA1c, fasting insulin and C-peptide, perform an oral glucose tolerance test, and assess insulin resistance to identify factors linked to pancreatogenic diabetes. A predictive model will be built to identify at-risk patients, with the goal of improving monitoring and prevention strategies after surgery. The study is conducted at the University Medical Centre Ljubljana and has no listed intervention beyond standard preoperative assessment and the planned surgery.
Why it matters
Potential benefit: If successful, the model could help clinicians tailor follow-up and preventive measures for patients at higher risk of pancreatogenic diabetes after surgery.
How similar studies have gone: There is currently no validated tool for predicting pancreatogenic diabetes after partial pancreatic resection, making this investigation relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥ 18 years * planned partial resection of the pancreas * absence of known diabetes before the procedure * absence of known borderline basal glycemia before the procedure * absence of impaired glucose tolerance before the procedure * signed written informed consent Exclusion Criteria: * known diabetes mellitus before the procedure * known borderline basal glycemia before the procedure * impaired glucose tolerance before the procedure * inability to provide informed consent * withdrawal of consent during the course of the study * total resection of the pancreas * a subsequent decision for conservative treatment (based on clinical characteristics at the time of the surgical procedure)
Where it's running
-
University Medical Centre Ljubljana
Ljubljana, Slovenia Recruiting
Study contacts
- Principal investigator: Jasna Klen, MD, PhD, Prof. — Ljubljana University Medical Centre, Zaloška cesta 7, Ljubljana
- Study coordinator: Brina Šket Tomšič, MD
- Email: brina.sket@kclj.si
- Phone: 00 386 1 522 2516
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Detecting pancreatic dysfunction in adults with type 2 diabetes
This project tests whether blood tests, a stool sample, and an ultrasound can identify pancreatogenic diabetes in adults with type 2 diabetes.
-
Lidocaine Infiltration to See If It Helps Inflammation and Brain Function After Head and Neck Cancer Surgery
This study tests whether different amounts of lidocaine injected into the surgical area can influence inflammation and brain-related outcomes after major head and neck cancer surgery in adults.
-
Minimal Sedation After Out-of-Hospital Cardiac Arrest
This study tests whether stopping continuous sedation right after return of circulation is as safe as keeping patients sedated in the early hours after OHCA.
-
Empagliflozin, Metformin, or both for muscle energy in adults with type 2 diabetes
This study tests whether empagliflozin, metformin, or their combination can improve skeletal muscle oxidative capacity and microvascular reactivity in adults recently diagnosed with type 2 diabetes.
-
Dexamethasone for tick-borne encephalitis
This trial will see if dexamethasone helps adults with confirmed tick-borne encephalitis who have meningitis, encephalitis, or meningomyelitis.
-
Dual PCSK9 Inhibition in secondary prevention for high LDL-C with statin intolerance
This study tests whether combining inclisiran and alirocumab lowers LDL cholesterol better than either drug alone in people with ASCVD who can’t tolerate statins.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.